The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?

Sep 14, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Ulrich Jäger, Medical University of Vienna, Vienna, AT, who also represents the Austrian CAR-T Cell Network. We asked, Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?

Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?

Ulrich Jäger talks about boosting the immune system during treatment for aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). He also discuss the PORTIA clinical study.